Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resection is Well Tolerated in Phase 2b Bladder Cancer Study

IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced results of a Phase 2b study of EOquin, in non-invasive bladder cancer and the presentation of preclinical data of SPI (IRL)-1620 and satraplatin at the annual meeting of the American Association of Cancer Research, held at the Los Angeles Convention Center in Los Angeles, California April 14-18, 2007.

Abstract #LB-359 -- Effect on Wound Healing and Pharmacokinetics of Single Intravesical Administration of Apaziquone (EOquin(R)) Immediately Following Transurethral Resection of Superficial Bladder Cancer -- Initial Results of a Phase 2b Study

The Phase 2b study was a multicenter, single-arm, open-label safety study with the objective of assessing the effect on surgical wound healing and systemic absorption of EOquin when given intravesically as a single dose immediately after transurethral resection of bladder tumor (TUR-BT). EOquin in 40mL of instillate was instilled into the bladder within 6 hours of TUR-BT. After an hour, the bladder was drained and patients were assessed for adverse events during the one-hour retention. Wound healing was assessed by cystoscopy performed at postoperative day 85.

Results

A total of 23 patients were enrolled and 20 patients received EOquin immediately following TUR-BT. EOquin instillation and retention were well tolerated by all patients, and no deaths or dropouts were reported. Four Serious Adverse Events were reported in three patients: two hematuria, one bacterial cystitis, and one urinary retention. Ten patients were examined by cystoscopy at day 85 and all showed complete reepithelialization without evidence of impaired wound healing. Neither the parent drug (EO9) nor its metabolite (EO54a) was detected in plasma samples utili
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/16/2009)... PITTSBURGH, Dec. 16 Cohera Medical Inc. ... in a study of its lead surgical adhesive ... major milestone in the company,s progression of the ... clinical investigation is a prospective, open-label, randomized study ... effect on wound drainage and associated complications in ...
(Date:12/16/2009)... Mass., Dec. 16 According to Millennium ... technology market intelligence, health care reforms in China ... market in 2009, and will continue to fuel ... Asia Pacific Markets for Interventional Cardiology Devices ... the Chinese government will allow the Chinese drug-eluting ...
(Date:12/16/2009)... Today, Avantium announced the,appointment of Gunnar Staaf ... Gunnar Staaf previously worked at Serentis Ltd, ... in a range of commercial and executive,positions. ... Avantium,s plan to,spin-out its pharmaceutical business. The ... based on its offering of proprietary,crystallization services ...
Breaking Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Avantium Appoints Gunnar Staaf as CEO Pharma 2Kensey Nash to Present at the Jefferies 3rd Annual Healthcare Conference 48487 1Anthropedia Foundation Charity Gala Murten Switzerland in the Presence of HSH Prince Albert II of Monaco 48483 1Anthropedia Foundation Charity Gala Murten Switzerland in the Presence of HSH Prince Albert II of Monaco 48483 2Latest trinational report presents most complete picture of North American industrial pollution 48480 1Latest trinational report presents most complete picture of North American industrial pollution 48480 2Latest trinational report presents most complete picture of North American industrial pollution 48480 3
... NEW YORK, Dec. 20 Intra-Cellular Therapies, Inc. ... insomnia (SMI) Phase 2,clinical study using its drug ... receptor antagonist and represents an important new,approach to ... separation of 5-HT2A,and dopamine receptor modulatory activities, ITI ...
... Labs, Inc. (OTC,Bulletin Board: GOVX), an Atlanta-based biotechnology ... retained Financial,Relations Board (FRB), as its Investor and ... vaccine human trial results need to be,conveyed to ... stated Kathy Waller, co-president of FRB., GeoVax ...
Other Medicine Technology:Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 2GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 3GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel 4
(Date:12/16/2009)... -- Losing has never felt so good for "The ... new lifestyle means continuing to make smart choices everyday ... is one healthy choice that is an important part ... can take. Every glass of milk has nine essential ... maintain normal blood pressure, and calcium and vitamin D ...
(Date:12/16/2009)... HealthSciences Institute will sponsor a ... teams and organizations who serve individuals at ... in employer, health plan, medical home and ... offer free, noncommercial webinars on topics, solutions ... management and care improvement. Each webinar will ...
(Date:12/16/2009)... an advance that could help ease health and environmental ... development of technology for changing the behavior of nanoparticles ... into the environment. Their study was published in ACS, ... Jarvie from the UK Centre for Ecology and Hydrology ... the production of nanoparticles particles less than 1/1000th ...
(Date:12/16/2009)... but use in humans is still far off , , WEDNESDAY, ... researchers have built and tested synthetic versions of the blood-clotting ... cases where blood just won,t stop flowing. , "We start ... degradable stitches, which dissolve in the body," said Erin B. ... University, and lead author of a report published Dec. ...
(Date:12/16/2009)... expert says, , , WEDNESDAY, Dec. 16 (HealthDay News) -- ... to die when they receive an implantable cardioverter defibrillator, ... people, ages 65 to 85, who were eligible for ... measure of the heart,s pumping ability) of 35 percent ... were treated with standard medication and an implanted defibrillator ...
Breaking Medicine News(10 mins):Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Behavior modification could ease concerns about nanoparticles 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Implanted Defibrillator Might Extend Life 2
... finds that taking oral contraceptive pills after caesarean sections ... ,Researchers at the Osaka University Graduate School of Medicine ... vaginal bleeding between menstrual cycles after a caesarean section. ... site of the surgery could result in scars in ...
... Pradesh is forming a network of youth, called the Red ... networking process, started recently, is part of the state's strategy ... so far. ,"Considering that 40 percent of AIDS ... the government has decided to establish Red Ribbon Clubs to ...
... or intuition is fleeting that we could use it in just ... research in this area. Researchers say that impressions// are formed even ... is just a split second to size up a person’s character ... ,With the help of timed experiments, participants were asked ...
... court battle against United Health Europe (UHE), the British arm ... run a GP surgery.// The company has been forced to ... people of Langwith, on the Derbyshire-Nottinghamshire border. ,The ... start the tendering process from scratch, after the ruling that ...
... International report, a Swiss research team has developed a ... which is better than// the already existing ones.The report ... detect anthrax spores that are used in biological warfare. ... by an anthrax attack that killed 5 people.They died ...
... the King's Fund advises that in view of the recent ... for cancer services should// be revised. ,This ... that was commissioned by charity Cancer Research UK. They have ... Plan to plan for future needs. ,Currently ...
Other Medicine News:Health News:Pensioner wins over a US healthcare giant 2Health News:Monoclonal Antibody based system for Anthrax detection 2Health News:Monoclonal Antibody based system for Anthrax detection 3
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: